Defining the role of RALA in CRC and its relationship with AURKA would be interesting for improving the selection of patients who could benefit from anti-AURKA therapies that are currently in clinical trials, with Alisertib (MLN8237) being the most promising of its inhibitors. The gene discussed is RALA; the disease is colorectal carcinoma.